ID: ALA5209279

Max Phase: Preclinical

Molecular Formula: C24H33N3O3

Molecular Weight: 411.55

Associated Items:

Representations

Canonical SMILES:  COC12CC3CC(NC(=O)NC4CCN(C(C)=O)CC4)(CC(C1)c1ccccc13)C2

Standard InChI:  InChI=1S/C24H33N3O3/c1-16(28)27-9-7-19(8-10-27)25-22(29)26-23-11-17-13-24(15-23,30-2)14-18(12-23)21-6-4-3-5-20(17)21/h3-6,17-19H,7-15H2,1-2H3,(H2,25,26,29)

Standard InChI Key:  NVZXSEMJVRVIAB-UHFFFAOYSA-N

Associated Targets(Human)

Epoxide hydratase 3844 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Epoxide hydratase 467 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 411.55Molecular Weight (Monoisotopic): 411.2522AlogP: 3.28#Rotatable Bonds: 3
Polar Surface Area: 70.67Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.33CX LogP: 0.89CX LogD: 0.89
Aromatic Rings: 1Heavy Atoms: 30QED Weighted: 0.80Np Likeness Score: -0.62

References

1. Codony S, Entrena JM, Calvó-Tusell C, Jora B, González-Cano R, Osuna S, Corpas R, Morisseau C, Pérez B, Barniol-Xicota M, Griñán-Ferré C, Pérez C, Rodríguez-Franco MI, Martínez AL, Loza MI, Pallàs M, Verhelst SHL, Sanfeliu C, Feixas F, Hammock BD, Brea J, Cobos EJ, Vázquez S..  (2022)  Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors.,  65  (20.0): [PMID:36222708] [10.1021/acs.jmedchem.2c00515]

Source